Study results highlight the use of truFreeze as the only FDA-cleared minimally-invasive spray cryotherapy platform that offers clinical benefit across the esophageal disease spectrum - from Barrett’s esophagus to Cancer
Study results highlight the use of truFreeze as the only FDA-cleared minimally-invasive spray cryotherapy platform that offers clinical benefit across the esophageal disease spectrum - from Barrett’s esophagus to Cancer
BOSTON, May 9, 2019 /PRNewswire/ -- CSA Medical today announced that the company’s truFreeze® Spray Cryotherapy will be featured in five sessions at Digestive Disease Week® (DDW®) 2019. The data, to be presented in three poster presentations and two podium presentations, highlight the clinical benefit that truFreeze provides to patients with Barrett’s esophagus (BE) and esophageal cancer (EC). DDW 2019, the world’s largest gathering of physicians, researchers and industry leaders in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, will be taking place in San Diego, May 18 - 21, 2019.
The truFreeze Spray Cryotherapy platform uses the extreme cold of liquid nitrogen (-196°C) to provide targeted, touchless ablation of diseased tissue, including cancer, while preserving underlying healthy tissue - in contrast to the scar tissue that forms after heat-based modalities such as radio-frequency ablation (RFA). truFreeze does not require the catheter to touch the tissue, enabling the treatment of nodular disease and unique morphologies. Additionally, truFreeze differentiates itself against other cryogens, such as nitrous oxide (-88 C), which doesn’t get tissue cold enough, fast enough to penetrate and ablate cancer.
“We are steadfast in our commitment of continuing clinical progress, and the data that will be presented at DDW 2019 underscore the broad utility of truFreeze as the only FDA-cleared therapy with proven benefit across the esophageal disease spectrum, from BE to cancer,” said Wendelin Maners, CSA’s President,. “These presentations add to the growing body of evidence that support truFreeze as an important ablative modality for managing esophageal disease from early dysplasia to malignancy to providing palliative care for patients who have difficulty swallowing. We look forward to sharing these new data with the broader community of physicians who are on the front lines of protecting and improving the standard of care in esophageal health.”
“These presentations add to the growing body of evidence that support truFreeze as an important ablative modality for managing esophageal disease from early dysplasia to malignancy to providing palliative care for patients who have difficulty swallowing.”
-Wendelin Maners, CSA’s President
CLICK TO TWEET
truFreeze will be featured in the following presentations at DDW 2019:
May 18, 2019: Poster Presentations
Session: Barrett’s Esophagus: Diagnosis, Management and Surveillance
Sa1137: Poster of Distinction: Nitrogen Spray Cryotherapy Eradicates Dysplasia In 87% and Intestinal Metaplasia In 65% of Patients With Barrett’s Esophagus: Results Of A U.S. Multicenter Registry
Time and Location: Noon – 2:00 pm; Halls C-E
Session: Esophagus 2
Sa1274: Liquid Nitrogen Spray Cryotherapy is Safe For Palliation of Esophageal Cancer: Interim Results From a Prospective Multicenter Study
Time and Location: Noon – 2:00 pm; Halls C-E
May 20, 2019: Poster Presentation
Session: Esophagus 1
Mo1172: Efficacy Of Cryotherapy As A Primary Treatment For Dysplastic Barrett’s Esophagus And Early Esophageal Neoplasia: A Systematic Review And Meta-Analysis
Time and Location: Noon – 2:00 pm; Halls C-E
May 20, 2019: Podium Presentations
Session: Evolving Use of Endoscopy in Esophageal Disease
547: Neoadjuvant Cryotherapy Improves Dysphagia And Increases Remission Rates In Advanced Esophageal Cancer
Time and Location: 8:30 – 8:45 am; Room 2
Session: Barrett’s Diagnosis and Therapy
639: Durability of Successful Eradication of Barrett’ Esophagus With Liquid Nitrogen Spray Cryotherapy: Results of a U.S. Multicenter Registry
Time and Location: 10:15 – 10:30 am; Room 2
About CSA Medical and truFreeze®
CSA Medical, Inc. develops and manufactures proprietary, interventional spray cryotherapy technology platforms harnessing the power of liquid nitrogen spray delivered by software driven devices with specialty catheters. Extremely cold (-196°C) liquid nitrogen spray flash freezes and destroys unwanted tissue while enabling a rejuvenative pattern of healing. CSA manufactures and distributes the truFreeze® system in the USA which is currently being utilized in over 125 leading hospitals and universities advancing therapy for patients affected by conditions such as Barrett’s esophagus, esophageal cancer, and benign and malignant airway obstructions. To learn more about CSA Medical’s technology, please visit www.csamedical.com.
truFreeze is a registered trademark of CSA Medical, Inc.
About DDW
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21, 2019, at the San Diego Convention Center. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
For further information contact:
Erich Sandoval
+1 917-497-2867
esandoval@lazarpartners.com
View original content:http://www.prnewswire.com/news-releases/csa-medicals-trufreeze-spray-cryotherapy-to-be-featured-during-digestive-disease-week-2019-300847414.html
SOURCE CSA Medical
